/HUMA
HUMA Stock - Humacyte, Inc.
Healthcare|BiotechnologyNASDAQ
$1.11-1.77%
$0.02 (-1.77%) • Jan 13
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.43
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+170.3%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HUMA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.10 – $1.12
TARGET (TP)$3.00
STOP LOSS$1.02
RISK/REWARD1:21.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.93
52W High$4.85
52W Low$0.91
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $1.56M | $1.26M | $1.49M |
| Gross Profit | $-7,190,000 | $-76,550,000 | $-6,690,000 | $-60,078,000 | $-52,587,000 |
| Gross Margin | N/A | N/A | -427.5% | -4756.8% | -3527.0% |
| Operating Income | $-114,398,000 | $-100,047,000 | $-84,578,000 | $-81,208,000 | $-64,599,999 |
| Net Income | $-148,701,000 | $-110,776,000 | $-11,965,000 | $-26,477,000 | $-66,524,000 |
| Net Margin | N/A | N/A | -764.5% | -2096.4% | -4461.7% |
| EPS | $-1.26 | $-1.07 | $-0.12 | $-0.66 | $-5.52 |
Company Overview
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$6
Average Target
↑ 440.5% Upside
Now
$4
Low
$6
Average
$15
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 27th 2025 | Barclays | Initiation | Overweight | $3.5 |
| May 14th 2025 | H.C. Wainwright | Resumed | Buy | $4 |
| December 20th 2024 | H.C. Wainwright | Reiterated | Buy | $15← $12 |
| December 11th 2023 | H.C. Wainwright | Initiation | Buy | $6 |
| August 14th 2023 | Piper Sandler | Upgrade | Neutral | $3.5← $2.75 |
| June 22nd 2023 | Cantor Fitzgerald | Initiation | Overweight | $6 |
| May 16th 2022 | Piper Sandler | Downgrade | Underweight | $4← $10 |
Earnings History & Surprises
HUMABeat Rate
42%
Last 19 quarters
Avg Surprise
-7.3%
EPS vs Estimate
Beats / Misses
8/8
3 met exactly
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q1 24
+4.0%
$-0.24vs$-0.25
Q2 24
-26.1%
$-0.29vs$-0.23
Q3 24
-17.4%
$-0.27vs$-0.23
Q4 24
-26.9%
$-0.33vs$-0.26
Q1 25
+30.4%
$-0.16vs$-0.23
Q2 25
+47.4%
$-0.10vs$-0.19
Q3 25
-60.0%
$-0.24vs$-0.15
Q4 25
+17.6%
$-0.14vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.15 | $-0.24 | -60.0% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.19 | $-0.10 | +47.4% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.23 | $-0.16 | +30.4% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.26 | $-0.33 | -26.9% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.23 | $-0.27 | -17.4% | ✗ MISS |
Q2 2024 | May 10, 2024 | $-0.23 | $-0.29 | -26.1% | ✗ MISS |
Q1 2024 | Mar 22, 2024 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.25 | $-0.25 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.22 | $-0.22 | 0.0% | = MET |
Q2 2023 | May 12, 2023 | $-0.22 | $-0.22 | 0.0% | = MET |
Q1 2023 | Mar 24, 2023 | $-0.24 | $-0.21 | +12.5% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.21 | $-0.25 | -19.0% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.22 | $-0.19 | +13.6% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-0.21 | $-0.22 | -4.8% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.21 | $-0.72 | -242.9% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.56 | $-0.17 | +70.2% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-0.90 | $-0.20 | +77.8% | ✓ BEAT |
Latest News
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
📈 PositiveBenzinga•Jan 8, 2026, 01:46 PM
Humacyte Announces Results Of 5-Yr Retrospective Analysis Of Hospital Charges, Payer Costs, And Healthcare Resource Utilization In Patients With Extremity Arterial Injury
➖ NeutralBenzinga•Jan 8, 2026, 01:10 PM
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
📈 PositiveBenzinga•Jan 5, 2026, 01:36 PM
Humacyte Plans To File MAA With Israel Ministry Of Health For Approval Of Acellular Tissue Engineered Vessel For Arterial Trauma Repair During Q1 2026
📈 PositiveBenzinga•Jan 5, 2026, 01:02 PM
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
📈 PositiveBenzinga•Dec 22, 2025, 02:59 PM
Humacyte Publishes Long-Term Data Assessing Durability Of Symvess In Extremity Arterial Trauma Patients In Journal Of Vascular Surgery Cases, Innovations And Techniques
➖ NeutralBenzinga•Dec 22, 2025, 01:04 PM
Humacyte May Offer And Sell Shares Of Common Stock Of Up To $60M From Time To Time Through TD Cowen, Acting As Agent
➖ NeutralBenzinga•Dec 16, 2025, 10:36 PM
Humacyte Terminates Revenue Interest And Option Agreements Dated May 12, 2023; Co To Pay Pay $38M Cash And Issue 5,725,190 Shares In Registered Offering
📉 NegativeBenzinga•Dec 15, 2025, 02:18 PM
Humacyte Terminates $80M Open Market Sale Agreement With Jefferies, Effective December 1; Company Is Not Subject To Any Termination Penalties Related To The Termination Of The Agreement
📉 NegativeBenzinga•Nov 26, 2025, 10:14 PM•Also:
BTIG Reiterates Buy on Humacyte, Maintains $6 Price Target
📈 PositiveBenzinga•Nov 21, 2025, 11:13 AM
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
📈 PositiveBenzinga•Nov 20, 2025, 02:25 PM
Benchmark Maintains Buy on Humacyte, Lowers Price Target to $11
📈 PositiveBenzinga•Nov 13, 2025, 06:33 PM
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 01:44 PM
Humacyte Announces Six Presentations Scheduled For VEITHsymposium Nov. 18-22
➖ NeutralBenzinga•Nov 13, 2025, 01:08 PM
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
📈 PositiveBenzinga•Nov 12, 2025, 07:14 PM
Humacyte Q3 EPS $(0.11) Beats $(0.16) Estimate, Sales $753.000K Miss $922.333K Estimate
➖ NeutralBenzinga•Nov 12, 2025, 12:08 PM
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
📈 PositiveBenzinga•Nov 10, 2025, 06:14 PM
Humacyte Presents 2-Yr Results From V007 Phase 3 Clinical Trial Of ATEV In AV Access For Hemodialysis Patients At ASN Kidney Week 2025
➖ NeutralBenzinga•Nov 10, 2025, 01:10 PM
Humacyte Publishes Study Showing Its Bioengineered Vessel, Symvess Demonstrated Comparable Short-Term Outcomes To Autologous Vein Grafts In Treating Extremity Arterial Trauma, With Similar Results For Patency, Limb Salvage, And Infection Rates
📈 PositiveBenzinga•Oct 30, 2025, 12:10 PM
BTIG Maintains Buy on Humacyte, Lowers Price Target to $6
➖ NeutralBenzinga•Oct 13, 2025, 12:06 PM
Frequently Asked Questions about HUMA
What is HUMA's current stock price?
Humacyte, Inc. (HUMA) is currently trading at $1.11 per share. The stock has moved -1.77% today.
What is the analyst price target for HUMA?
The average analyst price target for HUMA is $3.00, based on 1 analyst.
What sector is Humacyte, Inc. in?
Humacyte, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HUMA's market cap?
Humacyte, Inc. has a market capitalization of $0.16 billion, making it a small-cap company.
Does HUMA pay dividends?
No, Humacyte, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHV
Achieve Life Sciences, Inc.
$5.52
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$7.57
Mkt Cap: $0.2B
AVIR
Atea Pharmaceuticals, Inc.
$3.51
Mkt Cap: $0.3B
FHTX
Foghorn Therapeutics Inc.
$6.68
Mkt Cap: $0.4B
IMRX
Immuneering Corporation
$4.13
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.96
Mkt Cap: $0.2B
SGMT
Sagimet Biosciences Inc.
$6.21
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.46
Mkt Cap: $0.4B
VNDA
Vanda Pharmaceuticals Inc.
$7.44
Mkt Cap: $0.4B
VYGR
Voyager Therapeutics, Inc.
$4.02
Mkt Cap: $0.2B
Explore stocks similar to HUMA for comparison